Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell linesDevalingam Mahalingam, Éva Szegezdi|British Journal of Cancer|2009Cited by 41
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Laura Sinigaglia et al.|Cell Reports Medicine|2025Cited by 12
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockadeRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cancer Research|2023Cited by 1